Zacks Research Analysts Lower Earnings Estimates for TEVA

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) - Zacks Research lowered their Q3 2025 earnings estimates for Teva Pharmaceutical Industries in a research note issued on Wednesday, May 28th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.69 for the quarter, down from their prior forecast of $0.71. The consensus estimate for Teva Pharmaceutical Industries' current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries' Q4 2025 earnings at $0.60 EPS, FY2025 earnings at $2.40 EPS, Q1 2026 earnings at $0.48 EPS, Q2 2026 earnings at $0.64 EPS, Q3 2026 earnings at $0.79 EPS, FY2026 earnings at $2.60 EPS, Q1 2027 earnings at $0.64 EPS and FY2027 earnings at $2.80 EPS.

A number of other equities research analysts also recently issued reports on the stock. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their price target for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Truist Financial started coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They set a "buy" rating and a $25.00 price target for the company. Bank of America lifted their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Finally, Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $24.50.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock traded up $0.48 during midday trading on Monday, reaching $17.26. 9,478,222 shares of the company traded hands, compared to its average volume of 10,102,984. The firm's 50 day simple moving average is $15.55 and its two-hundred day simple moving average is $17.38. Teva Pharmaceutical Industries has a 1-year low of $12.47 and a 1-year high of $22.80. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The firm has a market cap of $19.56 billion, a PE ratio of -11.90, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The firm had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.99 billion. During the same quarter last year, the firm earned $0.48 earnings per share. The firm's revenue was up 1.9% compared to the same quarter last year.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Institutional investors have recently modified their holdings of the company. Robeco Institutional Asset Management B.V. raised its holdings in Teva Pharmaceutical Industries by 7.2% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock valued at $10,983,000 after acquiring an additional 33,277 shares during the last quarter. Pinnbrook Capital Management LP acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth $4,966,000. Asset Management One Co. Ltd. boosted its holdings in shares of Teva Pharmaceutical Industries by 14.6% during the fourth quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company's stock worth $10,414,000 after purchasing an additional 58,413 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 2,018.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,097,096 shares of the company's stock worth $23,368,000 after purchasing an additional 1,045,305 shares during the last quarter. Finally, Capital Wealth Planning LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 8.8% during the fourth quarter. Capital Wealth Planning LLC now owns 246,601 shares of the company's stock worth $5,435,000 after purchasing an additional 20,016 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.